Anti-inflammatory/infection PLA nanoparticles labeled with technetium 99m for in vivo imaging
Source abstract
Abstract
Despite advancements in treatment of infectious diseases, opportunistic pathogens continue to pose a worldwide threat. Identifying a source of infection/inflammation is often challenging which highlights the need of improved diagnostic agents. Using a model of local S. aureus infection, here we evaluated the potential of betamethasone or dexamethasone loaded in poly (lactic acid) nanoparticles and radiolabeled with 99mTc to detect an infection/inflammation site in vivo. A betamethasone and dexamethasone nanoparticles (NPs) with 200 and 220 nm in size, respectively, were created with a 98% 99mTc radiolabeling efficiency. When injected in infected mice, betamethasone NPs presented a higher accumulation in the infected hind paw in comparison with dexamethasone NPs. Our results suggest that this nanosystem may be a valid nanoradiopharmaceutical for the detection of inflammation/infection foci in vivo.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Orthopedic Infections and Treatments · Hematological disorders and diagnostics · Streptococcal Infections and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (27)
Show source-provided references
1. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515. https://doi.org/10.1021/mp800051m10.1021/mp800051m ↗
2. Bleeker-Rovers CP, van der Meer JW, Oyen WJ (2009) Fever of unknown origin. Semin Nucl Med 39:81–87. https://doi.org/10.1053/j.semnuclmed.2008.10.00210.1053/j.semnuclmed.2008.10.002 ↗
3. Bleeker-Rovers CP et al (2007) A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 34:694–703. https://doi.org/10.1007/s00259-006-0295-z10.1007/s00259-006-0295-z ↗
4. Boxio R, Bossenmeyer-Pourie C, Steinckwich N, Dournon C, Nusse O (2004) Mouse bone marrow contains large numbers of functionally competent neutrophils. J Leukoc Biol 75:604–611. https://doi.org/10.1189/jlb.070334010.1189/jlb.0703340 ↗
5. Colpan A, Onguru P, Erbay A, Akinci E, Cevik MA, Eren SS, Bodur H (2007) Fever of unknown origin: analysis of 71 consecutive cases. Am J Med Sci 334:92–96. https://doi.org/10.1097/MAJ.0b013e31812f564210.1097/MAJ.0b013e31812f5642 ↗
6. de Kleijn EM, van der Meer JW (1995) Fever of unknown origin (FUO): report on 53 patients in a Dutch university hospital. Neth J Med 47:54–6010.1016/0300-2977(95)00037-N ↗
7. dos Santos SN et al (2017) Avoiding the mononuclear phagocyte system using human albumin for mesoporous silica nanoparticle system. Microporous Mesoporous Mater 251:181–189. https://doi.org/10.1016/j.micromeso.2017.06.00510.1016/j.micromeso.2017.06.005 ↗
8. Feng X-R, Ding J-x, Gref R, Chen X-s (2017) Poly(β-cyclodextrin)-mediated polylactide-cholesterol stereocomplex micelles for controlled drug delivery. Chin J Polym Sci 35:693–699. https://doi.org/10.1007/s10118-017-1932-710.1007/s10118-017-1932-7 ↗
9. Fournier B, Philpott DJ (2005) Recognition of Staphylococcus aureus by the innate immune system. Clin Microbiol Rev 18:521–540. https://doi.org/10.1128/CMR.18.3.521-540.200510.1128/CMR.18.3.521-540.2005 ↗
10. Glaudemans AW, Israel O, Slart RH (2015) Pitfalls and limitations of radionuclide and hybrid imaging in infection and inflammation. Semin Nucl Med 45:500–512. https://doi.org/10.1053/j.semnuclmed.2015.02.00510.1053/j.semnuclmed.2015.02.005 ↗
11. Jann NJ et al (2009) Neutrophil antimicrobial defense against Staphylococcus aureus is mediated by phagolysosomal but not extracellular trap-associated cathelicidin. J Leukoc Biol 86:1159–1169. https://doi.org/10.1189/jlb.020905310.1189/jlb.0209053 ↗
12. Knockaert DC, Mortelmans LA, De Roo MC, Bobbaers HJ (1994) Clinical value of gallium-67 scintigraphy in evaluation of fever of unknown origin. Clin Infect Dis : Off Publ Infect Dis Soc Am 18:601–60510.1093/clinids/18.4.601 ↗
13. Li D, Ding JX, Tang ZH, Sun H, Zhuang XL, Xu JZ, Chen XS (2012) In vitro evaluation of anticancer nanomedicines based on doxorubicin and amphiphilic Y-shaped copolymers. Int J Nanomedicine 7:2687–2697. https://doi.org/10.2147/IJN.S3068710.2147/IJN.S30687 ↗
14. Li D et al (2013) Polymeric topology and composition constrained polyether-polyester micelles for directional antitumor drug delivery. Acta Biomater 9:8875–8884. https://doi.org/10.1016/j.actbio.2013.06.04110.1016/j.actbio.2013.06.041 ↗
15. Mourad O, Palda V, Detsky AS (2003) A comprehensive evidence-based approach to fever of unknown origin. Arch Intern Med 163:545–55110.1001/archinte.163.5.545 ↗
16. Okuyucu K et al. (2015) Evaluation of predictor variables of diagnostic [18F] FDG-PET/CT in fever of unknown origin. Q J Nucl Med Mol Imaging: Off Publ Ital Assoc Nucl Med
17. Pascual L et al (2017) Mesoporous silica as multiple nanoparticles systems for inflammation imaging as nano-radiopharmaceuticals. Microporous Mesoporous Mater 239:426–431. https://doi.org/10.1016/j.micromeso.2016.10.04110.1016/j.micromeso.2016.10.041 ↗
18. Petersdorf RG, Beeson PB (1961) Fever of unexplained origin: report on 100 cases. Medicine 40:1–3010.1097/00005792-196102000-00001 ↗
19. Psimadas D, Bouziotis P, Georgoulias P, Valotassiou V, Tsotakos T, Loudos G (2013) Radiolabeling approaches of nanoparticles with (99m) Tc. Contrast Media Mol Imaging 8:333–339. https://doi.org/10.1002/cmmi.153010.1002/cmmi.1530 ↗
20. Sá LTM, Simmons S, Missailidis S, MIPd S, Santos-Oliveira R (2013) Aptamer-based nanoparticles for cancer targeting. J Drug Target 21:427–434. https://doi.org/10.3109/1061186X.2012.76122210.3109/1061186X.2012.761222 ↗
21. Santos DM et al (2013) PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania. Nanomedicine 9:985–995. https://doi.org/10.1016/j.nano.2013.04.00310.1016/j.nano.2013.04.003 ↗
22. Schell-Frederick E, Fruhling J, Van der Auwera P, Van Laethem Y, Klastersky J (1984) 111Indium-oxine-labeled leukocytes in the diagnosis of localized infection in patients with neoplastic disease. Cancer 54:817–82410.1002/1097-0142(19840901)54:5<817::AID-CNCR2820540510>3.0.CO;2-J ↗
23. Shen K et al (2017) Targeted sustained delivery of antineoplastic agent with multicomponent polylactide stereocomplex micelle. Nanomedicine 13:1279–1288. https://doi.org/10.1016/j.nano.2016.12.02210.1016/j.nano.2016.12.022 ↗
24. Tesan F et al (2016) Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: preliminary studies. J Drug Delivery Sci Technol 36:95–98. https://doi.org/10.1016/j.jddst.2016.09.01110.1016/j.jddst.2016.09.011 ↗
25. Thais Braga L, Cristal C-C, Marta de Souza A, Marzena S, Emerson Soares B, Maria Angélica Vergara W, Ralph S-O (2016) Diagnosing gastrointestinal stromal tumours by single photon emission computed tomography using nano-radiopharmaceuticals based on bevacizumab monoclonal antibody. Biomed Phys Eng Express 2:04501710.1088/2057-1976/2/4/045017 ↗
26. Wang J, Xu W, Ding J, Lu S, Wang X, Wang C, Chen X (2015) Cholesterol-enhanced polylactide-based stereocomplex micelle for effective delivery of doxorubicin. Materials 8:21610.3390/ma8010216 ↗
27. Zazo H, Colino CI, Lanao JM (2016) Current applications of nanoparticles in infectious diseases. J Control Release: Off J Control Release Soc 224:86–102. https://doi.org/10.1016/j.jconrel.2016.01.00810.1016/j.jconrel.2016.01.008 ↗